Acquisition of the Immuno-Oncology Company SalvaRx
PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today.
OXFORD, UK, March 22nd, 2016
PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert adviser to 3Legs on its Reverse Takeover of SalvaRx. 3Legs Resources is an investment company that focuses on life sciences and related technologies. (To read the admission document, download the PDF)
SalvaRx is an immuno-oncology company developing novel therapeutics that stimulate the immune system to fight cancer. SalvaRx also owns over 60% of iOx Therapeutics, which is developing anti-cancer treatments based on invariant natural killer T-cells and is poised to undertake the first Phase I/II human trials.
Adrian Dawkes, Vice President, PharmaVentures said; “In the pivotal area of immuno-oncology we were pleased to be able to provide an expert assessment of the iOx technology to support 3Legs in its acquisition.”
Fintan Walton, Chief Executive of PharmaVentures said: “This is the twelfth independent expert report we have provided for companies raising finance, and the third during the recent upturn in IPO activities in the UK. Expert commercial and technical insight is a key component in company acquisitions especially where public markets are involved. PharmaVentures is able to provide valuable advisory services for our clients via our deep knowledge of the pharmaceutical and biotechnology sectors.”
For press enquiries, please contact:
Senior Marketing Manager
+44 (0) 1865 332700